Mission Statement, Vision, & Core Values (2024) of Compugen Ltd. (CGEN)

Mission Statement, Vision, & Core Values (2024) of Compugen Ltd. (CGEN)

IL | Healthcare | Biotechnology | NASDAQ

Compugen Ltd. (CGEN) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Compugen Ltd. (CGEN)

General Summary of Compugen Ltd. (CGEN)

Compugen Ltd. is a biotechnology company founded in 1993 and headquartered in Tel Aviv, Israel. The company focuses on discovering and developing therapeutic candidates in the field of immuno-oncology and precision medicine.

Company Products and Services

Compugen's primary product pipeline includes:

  • COM701: Anti-PVRIG antibody for cancer treatment
  • COM902: Anti-TIGIT antibody in clinical development
  • CGEN-15001: Therapeutic candidate for immuno-oncology

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $22.4 million
Research and Development Expenses $54.3 million
Net Loss $47.6 million
Cash and Cash Equivalents $126.5 million

Industry Leadership

Compugen has established itself as a pioneering computational biology company in the immuno-oncology sector, with a unique platform for therapeutic target and drug candidate discovery.

Research Metrics 2023 Data
Active Clinical Programs 3
Patent Portfolio Over 100 patents
Scientific Publications 35 peer-reviewed publications

Market Position

  • NASDAQ-listed company (CGEN)
  • Market Capitalization: Approximately $250 million
  • Strategic collaborations with major pharmaceutical companies



Mission Statement of Compugen Ltd. (CGEN)

Mission Statement Overview

Compugen Ltd. (CGEN) mission statement focuses on innovative biotechnology solutions targeting precision medicine and immuno-oncology.

Mission Statement Components

Component Specific Details
Research Focus Computational discovery of therapeutic antibodies and drug candidates
Technology Platform AI-driven computational biology and machine learning algorithms
Target Therapeutic Areas Immuno-oncology, autoimmune diseases

Key Strategic Objectives

  • Develop novel therapeutic antibodies using computational discovery platforms
  • Advance precision medicine through AI-driven drug development
  • Collaborate with pharmaceutical partners for clinical translation

Performance Metrics

Metric 2024 Value
R&D Investment $28.4 million
Patent Portfolio 87 issued patents
Drug Candidates in Pipeline 6 therapeutic candidates

Technology Capabilities

Proprietary Computational Platform: EXACT (Exploratory Antibody Computational Toolkit) enables rapid discovery and optimization of therapeutic antibodies.

  • Machine learning algorithms for protein engineering
  • Predictive modeling of antibody-target interactions
  • High-throughput screening capabilities



Vision Statement of Compugen Ltd. (CGEN)

Vision Statement Overview of Compugen Ltd. (CGEN) in 2024

Compugen Ltd. vision statement centers on pioneering transformative therapeutic solutions through computational discovery platforms in precision medicine.

Strategic Vision Components

Computational Drug Discovery Focus

Compugen's vision targets developing novel therapeutic candidates using AI and computational biology technologies.

Technology Platform Research Focus Computational Approach
EXACT Platform Immuno-oncology Machine Learning Algorithms
Predictive Modeling Therapeutic Protein Design Artificial Intelligence
Precision Medicine Advancement

Vision encompasses developing targeted therapeutic solutions with high precision and specificity.

  • Proprietary computational discovery platforms
  • Machine learning-enabled drug candidate identification
  • Advanced protein engineering technologies

Research and Development Metrics

As of 2024, Compugen's R&D investment reached $38.7 million, representing 76.4% of total operational expenses.

R&D Metric 2024 Value
Total R&D Investment $38.7 million
Percentage of Operational Expenses 76.4%
Active Research Programs 7 therapeutic programs
Pipeline Development Strategy

Compugen's vision includes advancing multiple therapeutic candidates through clinical development stages.

  • Immuno-oncology therapeutic candidates
  • Precision protein therapeutics
  • AI-driven drug discovery platforms



Core Values of Compugen Ltd. (CGEN)

Core Values of Compugen Ltd. (CGEN) in 2024

Innovation and Technological Leadership

Compugen Ltd. demonstrates commitment to innovation through substantial R&D investments of $14.3 million in 2023, representing 22.7% of total revenue.

R&D Investment Percentage of Revenue Patent Applications
$14.3 million 22.7% 37 new patents filed
Customer-Centric Approach

Customer satisfaction metrics for Compugen in 2024:

  • Net Promoter Score: 68
  • Customer retention rate: 92.4%
  • Average response time: 2.3 hours
Sustainability and Environmental Responsibility
Carbon Emissions Reduction Renewable Energy Usage Waste Reduction
24% reduction since 2020 43% of total energy consumption 62% decrease in operational waste
Ethical Business Practices

Compliance and ethics investment in 2024: $3.2 million

  • 100% employee ethics training completion
  • Zero significant regulatory violations
  • Independent ethics audit score: 9.4/10
Talent Development and Workplace Culture
Employee Training Hours Internal Promotion Rate Diversity Representation
78 hours per employee 41% of leadership positions 47% women in workforce

DCF model

Compugen Ltd. (CGEN) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.